Canadian boycott of U.S. spirits in trade war hurts broader alcohol sales, analysis says

Canada should rethink its approach to prostate cancer screening, which uses a controversial blood test that an expert task force encouraged doctors to abandon more than a decade ago, according to a new paper led by a group of Toronto urologists and oncologists.In an article published Friday in The Lancet Regional Health – Americas, the authors argue for a population-wide trial that would offer the blood test, known as the prostate-specific antigen test, or PSA test, to men at elevated risk of prostate cancer, likely including Black men and those with a family history of the disease.